Strategies to target HER2/neu overexpression for cancer therapy
- 22 May 2003
- journal article
- review article
- Published by Elsevier BV in Drug Resistance Updates
- Vol. 6 (3), 129-136
- https://doi.org/10.1016/s1368-7646(03)00040-2
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- HER-Targeted Tyrosine-Kinase InhibitorsOncology, 2002
- Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthCancer Cell, 2002
- Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancerSeminars in Oncology, 2002
- HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancerSeminars in Oncology, 2002
- Trastuzumab in the treatment of non–small cell lung cancerSeminars in Oncology, 2002
- Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2 –specific hammerhead ribozymeCancer Gene Therapy, 2001
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatmentGene, 1995
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neuBreast Cancer Research and Treatment, 1992
- The neu oncogene encodes an epidermal growth factor receptor-related proteinNature, 1986